^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Oral Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + TheraCIM (nimotuzumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report
Excerpt:
This is the first case describing the efficacy and safety of nivolumab plus radiotherapy and nimotuzumab in an OSCC patient with a strong PD-L1 expression, showing a tolerable safety profile and a promising response.
DOI:
10.21037/atm.2020.02.96
